Determination of central pain modulation biomarkers to characterize and profile cancer patients with refractory pain

niversity of Santiago de Compostela0 sites750 target enrollmentMay 30, 2023

Overview

No summary available.

Registry

who.int

Start Date

May 30, 2023

End Date

May 1, 2026

Last Updated

2 years ago

Study Type

Observational

Sex

All

Sponsor

niversity of Santiago de Compostela

•Cancer patients with pain:
•1\. Adult subjects \= 18 years old
•2\. Able to provide informed consent to participate in the study
•3\. Able to self\-report pain
•4\. To have a diagnosis of cancer affecting the lung, breast, pancreas or colon (with metastases or not)
•5\. The life expectancy of at least six months
•6\. Cancer pain persisting despite best\-tolerated pharmacological treatment
•7\. Pain rated \=5 on a 0\-10 Numeric Rating Scales (NRS) persisting for over 1 month prior to enrolment
•8\. Ability to use the internet and WhatsApp or have a person (relative, caregiver) to help them
•Cancer patients with no pain:

•Cancer patients with pain:
•1\. Pregnant women or women of fertile age that did not have efficacious contraception during the whole period of the study
•2\. Neurological or psychiatric diseases (except anxiety or depression)
•3\. Unstable medical conditions (e.g., uncontrolled diabetes, uncompensated cardiac issues, heart failure or chronic obstructive pulmonary disease)
•4\. History of neurosurgery, traumatic brain injury with loss of consciousness, and/or cortical lesions
•5\. Present risk factors for receiving tES (e.g., history of epilepsy, metal devices in the brain, etc.)
•6\. History of non\-malignant chronic pain
•Cancer patients with no pain:
•1\. Pregnant women or women of fertile age that did not have efficacious contraception during the entire period of the study.
•2\. Neurological or psychiatric diseases (except anxiety or depression).